Edition:
United Kingdom

Proteostasis Therapeutics Inc (PTI.OQ)

PTI.OQ on NASDAQ Stock Exchange Global Market

4.96USD
18 May 2018
Change (% chg)

-- (--)
Prev Close
$4.96
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
327,637
52-wk High
$8.61
52-wk Low
$1.41

Select another date:

Mon, May 7 2018

BRIEF-Proteostasis Therapeutics Says CFO Helen Boudreau Provided Notice Of Resignation

* PROTEOSTASIS THERAPEUTICS SAYS ON MAY 2, CFO AND TREASURER, HELEN BOUDREAU, PROVIDED NOTICE OF RESIGNATION TO PURSUE ANOTHER PROFESSIONAL OPPORTUNITY

BRIEF-Proteostasis Therapeutics Files For Mixed Shelf Of Up To $100 Mln

* PROTEOSTASIS THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING Source text: [https://bit.ly/2H14NPj] Further company coverage:

BRIEF-Proteostasis Receives FDA Fast Track Designation For Triple Combination Program In Patients With Cystic Fibrosis

* PROTEOSTASIS THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR TRIPLE COMBINATION PROGRAM IN PATIENTS WITH CYSTIC FIBROSIS

BRIEF-Proteostasis Announces Proposed Public Offering Of Common Stock

* PROTEOSTASIS THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Proteostasis Therapeutics Expects Cash, Cash Equivalents,Short-Term Investments To Be Enough To Fund Its Operating Expenses

* PROTEOSTASIS THERAPEUTICS REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIEF-Proteostasis Therapeutics Sees Cash, Cash Equivalents Balance As Of Dec 31, Sufficient To Fund Operations Into Early 2019​

* PROTEOSTASIS THERAPEUTICS INC - CO ESTIMATES CASH, CASH EQUIVALENTS BALANCE AS OF DEC 31, 2017, SUFFICIENT TO FUND OPERATIONS INTO EARLY 2019​ Source text: (http://bit.ly/2FWFOfk) Further company coverage:

BRIEF-Proteostasis Therapeutics Prices Public Offering Of 8 Mln Shares At $5/Share

* PROTEOSTASIS THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK

BRIEF-Proteostasis Therapeutics Announces Positive Clinical Results From Cystic FibrosisStudies

* PROTEOSTASIS THERAPEUTICS ANNOUNCES POSITIVE CLINICAL RESULTS FROM STUDIES OF PTI-428, PTI-801 AND PTI-808 IN HEALTHY VOLUNTEERS AND PATIENTS WITH CYSTIC FIBROSIS

Select another date: